

ABSTRACT OF THE DISCLOSURE

Specific Cytokine Antagonists, including TNF antagonists and/or Interleukin-1 antagonists, are used as novel therapeutic agents for the treatment of hearing loss, including presbycusis and 5 other forms of sensorineural hearing loss. The present invention provides a method for inhibiting the action of TNF and/or IL-1 antagonists for treating hearing loss in a human by administering a TNF antagonist and/or an IL-1 antagonist for reducing the inflammation affecting the auditory apparatus of said human, or for 10 modulating the immune response affecting the auditory apparatus of said human, by administering a therapeutically effective dosage level to said human of a TNF antagonist and/or an IL-1 antagonist. Administration may be systemic, through the subcutaneous, intramuscular, oral, or intravenous routes; or by delivering an 15 anatomically localized application in the region of the head. The TNF antagonist is selected from the group consisting of etanercept, infliximab, D2E7, CDP 571, or thalidomide; and the IL-1 antagonist is either IL-1 RA or IL-1R type II receptor. Antiviral agents may be added for treating certain patients.

REFERENCES

Adams et al. (1989), "Deafness, Dizziness, and Disorders of Equilibrium," *Principles of Neurology* Ch.14:226-246.

Arck, P.C., Troutt, A.B., Clark, D.A. (1997). Soluble receptors neutralizing TNF- α and IL-1 block stress-triggered murine abortion.
5 Am J Reprod Immunol 37, 262-266.

Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. *Science* 1993;261:472-5.

Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. *International Reviews of Immunology* 1998;16:457-99.

Eldman M, Brennan FM, Maini RN. The role of cytokines in rheumatoid arthritis. *Ann Rev Immunol* 1996;14:397.

Hefti (1994), "Neurotrophic Factor Therapy for Nervous System Degenerative Diseases," *J. Neurobiol.* 25:1418-1435.

Lovell DJ, Giannini EH, Reiff, A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. *N Engl J Med* 2000;342(11):763-9.

Murray, K.M., Dahl, S.L. (1997). Recombinant human tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc) in rheumatoid arthritis. *Ann Pharmacother* 31, 1335-1338.

10 Mohler, K.M., Torrance, D.S., Smith, C.A., Goodwin, R.G., Stremler, K.E., Fung, V.P., Madani, H., Widmer, M.B. (1993). Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. *J Immunol* 151, 1548-1561.

15 Nadol (1981) "The Aging Peripheral Hearing Mechanism," *Aging: Communication Processes and Disorders* Ch. 4:63-85.

16 Nadol (1993), "Hearing Loss," *New England J. of Medicine* 329:1092-1102.

Schuknecht (1974) *Pathology of the Ear* pp. 388-403.

Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA, Giri JG, Colotta F, Re F, Mantovani A, Shanebeck K, Grabstein KH, Dower SK. Interleukin 1 signaling occurs exclusively via the type I receptor.

20 Proc Natl Acad Sci U S A 1993;90:6155-9.

Spoendlin (1984), "Primary Neurons and Synapses," Ultrastructural Atlas of the Inner Ear Ch. 6:133-164.

Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.-P., Nicholl, J.K., Sutherland, G.R., Davis Smith, T., Rauch, C., Smith, 5 C.A., Goodwin, R.G. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity* 3, 673-682.

Wilson et al. (1980), "The Efficacy of Steroids in the Treatment of Idopathic Sudden Hearing Loss," *Arch Otolaryngol* 106:772-776.

10 Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. *J Immunol* 1993;151:6602.